Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil

Brazilian Journal of Infectious Diseases

Volumn 21, Issue 1, 2017, Pages 63-70

  Zerbini, Cristiano A F ^a   Ribeiro dos Santos, Rodrigo ^b   Jose Nunes, Maria ^a   Soni, Jyoti ^c   Li, Ping ^d   Jain, Varsha K ^d   Ofori Anyinam, Opokua ^e  

^a Centro Paulista de Investigacao Clinica   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c GlaxoSmithKline Pharmaceuticals Ltd   (India)

^d GLAXOSMITHKLINE   (United States)

^e GSK   (Belgium)

Author keywords

Adults; Brazil; Immunogenicity; Influenza; Quadrivalent; Safety; Vaccine

Indexed keywords

INFLUENZA VACCINE; INACTIVATED VACCINE; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BRAZIL; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAINTNESS; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA B VICTORIA; INFLUENZA B YAMAGATA; INFLUENZA VACCINATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRURITUS; SEASONAL INFLUENZA; SHIVERING; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VACCINE IMMUNOGENICITY; ADVERSE EFFECTS; AGE; BLOOD; CLINICAL TRIAL; HEMAGGLUTINATION; IMMUNOLOGY; INFLUENZA, HUMAN; MIDDLE AGED; REPRODUCIBILITY; TIME FACTOR; TREATMENT OUTCOME; VACCINATION; YOUNG ADULT;

ADULT; AGE FACTORS; ANTIBODIES, VIRAL; BRAZIL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTINATION, VIRAL; HUMANS; IMMUNOGENICITY, VACCINE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT OUTCOME; VACCINATION; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 85008339535     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2016.10.003     Document Type: Article

References (33)

1. 1 United States Centers for Disease Control and Prevention. http://www.cdc.gov/flu/weekly/pastreports.htm. Past weekly surveillance reports.
2. 2 Caini, S., Huang, Q.S., Ciblak, M.A., et al. Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study. Influenza Other Respir Viruses 9:Suppl 1 (2015), 3–12.
3. 3 Oliveira, M., Motta, F., Soares, S., Resende, P., Carney, S., Costa, J., Mismatch between vaccine strains and circulating influenza B viruses in different regions of Brazil: 2001–2013. Options for the control of influenza. Cape Town, 2013, 382 Available at: http://optionsviii.controlinfluenza.com/.
4. 4 Paiva, T., Benega, M., Silva, D., Santos, K., Pereira, J., Sasaki, N., Influenza virus surveillance conducted by the Institute Adolfo Lutz, São Paulo, SP, Brazil: 2013 influenza season. Options for the control of influenza. Cape Town, 2013, 599 Available at: http://optionsviii.controlinfluenza.com/.
5. 5 Perosa, A., Bellei, N., Influenza B circulation during twelve influenza seasons (2001–2013) in a tertiary hospital in Sao Paulo, Brazil. Options for the control of influenza. Cape Town, 2013, 637 Available at: http://optionsviii.controlinfluenza.com/.
6. 6 World Health Organization. Influenza, FluNet. http://www.who.int/influenza/gisrs_laboratory/flunet/en/.
7. 7 Barros, E.N., Cintra, O., Rossetto, E., Freitas, L., Colindres, R., Patterns of influenza B circulation in Brazil and its relevance to seasonal vaccine composition. Braz J Infect Dis, 2015.
8. 8 Reed, C., Meltzer, M.I., Finelli, L., Fiore, A., Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 30 (2012), 1993–1998.
9. 9 Heikkinen, T., Ikonen, N., Ziegler, T., Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999–2012. Clin Infect Dis 59 (2014), 1519–1524.
10. 10 Beran, J., Peeters, M., Dewe, W., Raupachova, J., Hobzova, L., Devaster, J.M., Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis, 13, 2013, 224.
11. 11 Block, S.L., Falloon, J., Hirschfield, J.A., et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J 31 (2012), 745–751.
12. 12 Block, S.L., Yi, T., Sheldon, E., Dubovsky, F., Falloon, J., A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine 29 (2011), 9391–9397.
13. 13 Cadorna-Carlos, J.B., Nolan, T., Borja-Tabora, C.F., et al. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: a randomized, controlled, phase III trial. Vaccine 33 (2015), 2485–2492.
14. 14 Domachowske, J.B., Pankow-Culot, H., Bautista, M., et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3–17 years. J Infect Dis 207 (2013), 1878–1887.
15. 15 Gorse, G.J., Falsey, A.R., Ozol-Godfrey, A., Landolfi, V., Tsang, P.H., Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults. Vaccine 33 (2015), 1151–1159.
16. 16 Greenberg, D.P., Robertson, C.A., Noss, M.J., Blatter, M.M., Biedenbender, R., Decker, M.D., Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 31 (2013), 770–776.
17. 17 Kieninger, D., Sheldon, E., Lin, W.Y., et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. BMC Infect Dis, 13, 2013, 343.
18. 18 Pepin, S., Donazzolo, Y., Jambrecina, A., Salamand, C., Saville, M., Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine 31 (2013), 5572–5578.
19. 19 Rodriguez Weber, M.A., Claeys, C., Aranza Doniz, C., et al. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18–47 months of age. Pediatr Infect Dis J 33 (2014), 1262–1269.
20. 20 Tinoco, J.C., Pavia-Ruz, N., Cruz-Valdez, A., et al. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial. Vaccine 32 (2014), 1480–1487.
21. 21 European Medicines Agency, Guideline on influenza vaccines. Non-clinical and clinical module. 2014, July EMA/CHMP/VWP/457259/2014.
22. 22 Hehme, N., Künzel, W., Petschke, F., et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Invest 22 (2002), 751–769.
23. 23 Govaert, T.M., Sprenger, M.J., Dinant, G.J., Aretz, K., Masurel, N., Knottnerus, J.A., Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial. Vaccine 12 (1994), 1185–1189.
24. 24 Iorio, A.M., Camilloni, B., Basileo, M., Neri, M., Lepri, E., Spighi, M., Effects of repeated annual influenza vaccination on antibody responses against unchanged vaccine antigens in elderly frail institutionalized volunteers. Gerontology 53 (2007), 411–418.
25. 25 Jain, V.K., Chandrasekaran, V., Wang, L., Li, P., Liu, A., Innis, B.L., A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine. BMC Infect Dis, 14, 2014, 133.
26. 26 Nabeshima, S., Kashiwagi, K., Murata, M., Kanamoto, Y., Furusyo, N., Hayashi, J., Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive years. J Med Virol 79 (2007), 320–325.
27. 27 Treanor, J.J., Campbell, J.D., Brady, R.C., et al. Rapid licensure of a new, inactivated influenza vaccine in the United States. Hum Vaccin 1 (2005), 239–244.
28. 28 Mosterin Hopping, A., McElhaney, J., Fonville, J.M., Powers, D.C., Beyer, W.E., Smith, D.J., The confounded effects of age and exposure history in response to influenza vaccination. Vaccine 34 (2016), 540–546.
29. 29 Haber, P., Moro, P.L., Lewis, P., Woo, E.J., Jankosky, C., Cano, M., Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013–May 31, 2015. Vaccine, 2016.
30. 30 Carrat, F., Flahault, A., Influenza vaccine: the challenge of antigenic drift. Vaccine 25 (2007), 6852–6862.
31. 31 Ambrose, C.S., Levin, M.J., The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 8 (2012), 81–88.
32. 32 Savy, V., Ciapponi, A., Bardach, A., et al. Burden of influenza in Latin America and the Caribbean: a systematic review and meta-analysis. Influenza Other Respir Viruses 7 (2013), 1017–1032.
33. 33 Bricks, L., Lopez, J.G., Macabeo, B., et al. Public health and economic impact of a quadrivalent influenza vaccine in comparison to the trivalent influenza vaccine in Brazil over the period of 2010–2013. Value Health 18 (2015), A578–A579.